tetrabenazine

Summary

Summary: A drug formerly used as an antipsychotic but now used primarily in the treatment of various movement disorders including tardive dyskinesia. Tetrabenazine blocks uptake into adrenergic storage vesicles and has been used as a high affinity label for the vesicle transport system.

Top Publications

  1. ncbi Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders
    David R P Guay
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Am J Geriatr Pharmacother 8:331-73. 2010
  2. ncbi Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Houston, TX, USA
    Expert Rev Neurother 11:1509-23. 2011
  3. ncbi Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study
    Itzhak Kimiagar
    Department of Neurology, Movement Disorders Unit, Assaf Harofeh Medical Center, Zerifin, Israel
    J Neurol 259:660-4. 2012
  4. ncbi Postthalamic stroke dystonic choreoathetosis responsive to tetrabenazine
    Rocco Salvatore Calabrò
    IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy
    Ann Pharmacother 45:e65. 2011
  5. pmc In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers
    Rajesh Narendran
    Department of Radiology, University of Pittsburgh, USA
    Am J Psychiatry 169:55-63. 2012
  6. pmc Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine
    Yelena Ugolev
    From the Department of Biological Chemistry, Alexander A Silberman Institute of Life Sciences, Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Biol Chem 288:32160-71. 2013
  7. pmc Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression
    Eric J Nunes
    Department of Psychology, University of Connecticut, Storrs, Connecticut 06269 1020, Universitat Bonn, Pharma Zentrum Bonn, Pharmazeutisches Institut, Pharmazeutische Chemie, 53121 Bonn, Germany, and Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, 12071 Castello, Spain
    J Neurosci 33:19120-30. 2013
  8. pmc Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients
    Robert Fekete
    Department of Neurology, New York Medical College, Fourth Floor, Munger Pavilion, 40 Sunshine Cottage Road, Valhalla, NY 10595, USA
    Parkinsonism Relat Disord 18:896-8. 2012
  9. ncbi Tetrabenazine treatment for Huntington's disease-associated chorea
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 25:300-2. 2002
  10. ncbi A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008

Detail Information

Publications202 found, 100 shown here

  1. ncbi Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders
    David R P Guay
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Am J Geriatr Pharmacother 8:331-73. 2010
    ..b>Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and ..
  2. ncbi Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Houston, TX, USA
    Expert Rev Neurother 11:1509-23. 2011
    b>Tetrabenazine (TBZ; Xenazine) is a potent, selective, reversible depletor of monoamines from nerve terminals. TBZ inhibits the vesicular monoamine transporter type 2 which, in humans, is expressed nearly exclusively in the brain...
  3. ncbi Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study
    Itzhak Kimiagar
    Department of Neurology, Movement Disorders Unit, Assaf Harofeh Medical Center, Zerifin, Israel
    J Neurol 259:660-4. 2012
    ..Our objective was to retrospectively analyze a combination of tetrabenazine (TBZ), clonazepam (CLONAZ) and clozapine (CLOZ) used simultaneously for TD in psychotic patients...
  4. ncbi Postthalamic stroke dystonic choreoathetosis responsive to tetrabenazine
    Rocco Salvatore Calabrò
    IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy
    Ann Pharmacother 45:e65. 2011
    To describe the case of a woman with poststroke choreoathetosis whose symptoms improved after treatment with tetrabenazine.
  5. pmc In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers
    Rajesh Narendran
    Department of Radiology, University of Pittsburgh, USA
    Am J Psychiatry 169:55-63. 2012
    ....
  6. pmc Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine
    Yelena Ugolev
    From the Department of Biological Chemistry, Alexander A Silberman Institute of Life Sciences, Hebrew University of Jerusalem, 91904 Jerusalem, Israel
    J Biol Chem 288:32160-71. 2013
    ..b>Tetrabenazine (TBZ) is a non-competitive inhibitor of VMAT2 that is used in the treatment of hyperkinetic disorders ..
  7. pmc Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression
    Eric J Nunes
    Department of Psychology, University of Connecticut, Storrs, Connecticut 06269 1020, Universitat Bonn, Pharma Zentrum Bonn, Pharmazeutisches Institut, Pharmazeutische Chemie, 53121 Bonn, Germany, and Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, 12071 Castello, Spain
    J Neurosci 33:19120-30. 2013
    ..present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT) inhibitor tetrabenazine. Tetrabenazine produces depressive symptoms in humans and, because of its selective inhibition of VMAT-2, it ..
  8. pmc Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients
    Robert Fekete
    Department of Neurology, New York Medical College, Fourth Floor, Munger Pavilion, 40 Sunshine Cottage Road, Valhalla, NY 10595, USA
    Parkinsonism Relat Disord 18:896-8. 2012
    Impairment in computerized dynamic posturography scores has been documented in Huntington disease patients. Tetrabenazine is approved to treat chorea in Huntington disease, but its effect on posturography scores, and balance in general, ..
  9. ncbi Tetrabenazine treatment for Huntington's disease-associated chorea
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Neuropharmacol 25:300-2. 2002
    b>Tetrabenazine (TBZ), a monoamine depleter and dopamine receptor blocker, is used to treat a variety of hyperkinetic movement disorders...
  10. ncbi A study of chorea after tetrabenazine withdrawal in patients with Huntington disease
    Samuel Frank
    Department of Neurology, Boston University School of Medicine, Boston, MA, USA
    Clin Neuropharmacol 31:127-33. 2008
    To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal.
  11. ncbi Tetrabenazine therapy of pediatric hyperkinetic movement disorders
    Samay Jain
    Department of Neurology, Movement Disorders Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Mov Disord 21:1966-72. 2006
    b>Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited...
  12. ncbi Tourette's syndrome and role of tetrabenazine: review and personal experience
    Mauro Porta
    Tourette Clinic and Functional Neurosurgery, IRCCS Galaezzi Hospital, Milan, Italy
    Clin Drug Investig 28:443-59. 2008
    ..b>Tetrabenazine is such an agent; it depletes presynaptic dopamine and serotonin stores and blocks postsynaptic dopamine ..
  13. ncbi Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs
    William G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    J Child Neurol 23:435-7. 2008
    Weight gain occurs with most neuroleptic drugs used to treat tics. Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor, inhibits dopamine release...
  14. pmc In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine
    Hank F Kung
    Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Nucl Med Biol 35:825-37. 2008
    ..The hydrolyzable epoxide group of (+)4 may provide a mechanism for shifting biodistribution from liver to kidney, thus reducing the background signal...
  15. ncbi Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine
    Livia Brusa
    UOC Neurologia, Ospedale Sant Eugenio, Rome, Italy
    Mov Disord 24:126-9. 2009
    ..a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD)...
  16. ncbi Tetrabenazine for the treatment of tardive dyskinesia
    Jonathan G Leung
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Ann Pharmacother 45:525-31. 2011
    To evaluate the safety and effectiveness of tetrabenazine for the treatment of tardive dyskinesia.
  17. pmc Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
    Samuel Frank
    BMC Neurol 9:62. 2009
    b>Tetrabenazine (TBZ) selectively depletes central monoamines by reversibly binding to the type-2 vesicular monoamine transporter...
  18. ncbi Role of tetrabenazine for Huntington's disease-associated chorea
    Linda H Poon
    University of California at San Francisco, CA, USA
    Ann Pharmacother 44:1080-9. 2010
    To review the pharmacology, pharmacokinetics, efficacy, and safety of tetrabenazine for the treatment of Huntington's disease (HD)-associated chorea.
  19. ncbi Is history of depression a contraindication to treatment with tetrabenazine?
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Neuropharmacol 29:259-64. 2006
    To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom.
  20. ncbi Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:193-7. 2007
    We sought to review the long-term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders...
  21. ncbi Short-term effects of tetrabenazine on chorea associated with Huntington's disease
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:10-3. 2007
    We sought to assess the short-term clinical effects of tetrabenazine (TBZ) on choreic movements in Huntington's disease patients. A total of 10 patients on stable doses of TBZ were enrolled in this observational study...
  22. ncbi The long-term effect of tetrabenazine in the management of Huntington disease
    Alfonso Fasano
    Istituto di Neurologia, Universita Cattolica del Sacro Cuore, Roma, Italy
    Clin Neuropharmacol 31:313-8. 2008
    To enhance the knowledge on the long-term efficacy and safety of tetrabenazine (TBZ) in managing chorea.
  23. ncbi Tetrabenazine treatment in movement disorders
    D Paleacu
    Neurology Service and Memory Clinic, Abarbanel Mental Health Center, Bat Yam, affiliated to the Sackler School of Medicine, Tel Aviv University, Israel
    Clin Neuropharmacol 27:230-3. 2004
    b>Tetrabenazine (TBZ) is a catecholamine depletor used for the treatment of a variety of movement disorders...
  24. ncbi Tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
    Expert Rev Neurother 6:7-17. 2006
    b>Tetrabenazine, a dopamine-depleting agent first synthesized half a century ago, was initially developed for the treatment of schizophrenia...
  25. ncbi Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease
    Nicolaas I Bohnen
    Department of Radiology, Division of Nuclear Medicine, The University of Michigan Medical School, Ann Arbor, 48109 0028, USA
    J Cereb Blood Flow Metab 26:1198-212. 2006
    ..We conclude that (+)-[(11)C]DTBZ-PET imaging displays many properties necessary of a PD biomarker...
  26. ncbi Imipramine and tetrabenazine: effects on monoamine receptor binding sites and phosphoinositide hydrolysis
    P D Butler
    New York State Psychiatric Institute, NY
    Eur J Pharmacol 160:93-100. 1989
    Treatment of rats for 21 days with tetrabenazine, a drug which depletes monoamines and is used behaviorally to screen for antidepressants, significantly decreased 5-HT2 receptor density, increased alpha 1-adrenoceptor density but did not ..
  27. ncbi A case of PANDAS treated with tetrabenazine and tonsillectomy
    Francesca Romana Fusco
    Santa Lucia Foundation IRCCS Hospital, Department F and Laboratory of Neuroanatomy, Santa Lucia Foundation IRCCS at the European Center for Brain Research, Rome, Italy
    J Child Neurol 25:614-5. 2010
    ..Moreover, serum antibrain antibodies were present. The patient was initially treated with tetrabenazine 12.5 mg twice daily with remission of the neurological symptoms...
  28. pmc Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine
    Anthony Raffo
    Department of Medicine, BB 20 06, Columbia University Medical Center, 650 West 168th Street, New York, New York 10032, USA
    J Endocrinol 198:41-9. 2008
    ..Using a VMAT2-specific antagonist, tetrabenazine (TBZ), we studied glucose homeostasis, insulin secretion both in vivo and ex vivo in cultures of purified ..
  29. ncbi Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas
    Hsin Hsin Tsao
    Department of Nuclear Medicine, Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
    Nucl Med Biol 38:1029-34. 2011
    ..In the present study, we explore the background binding characteristics of [(18)F]AV-133 in rat pancreas...
  30. ncbi Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats
    T Satou
    2nd Department of Pathology, Kinki University School of Medicine, Osaka, Japan
    Exp Toxicol Pathol 53:303-8. 2001
    We investigated the effects of a 7 day repetitive administration of tetrabenazine (TBZ), which depletes monoamines, on both locomotor behavior and histomorphometrial findings of substantia nigra in rats...
  31. ncbi Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol
    W G Ondo
    Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Am J Psychiatry 156:1279-81. 1999
    b>Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders. The authors studied the use of tetrabenazine for tardive dyskinesia.
  32. ncbi Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain
    Michael R Kilbourn
    Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Nucl Med Biol 31:591-5. 2004
    ..17+/-0.39, N=52), again irrespective of radionuclide or sex. These studies demonstrate that use of a consistent in vivo technique can provide reliable measures of specific binding of radioligands to high affinity sites in the rat brain...
  33. ncbi The effect of rare human sequence variants on the function of vesicular monoamine transporter 2
    Jonathon Burman
    Department of Neurology, UCSF School of Medicine, San Francisco, CA 94143 2140, USA
    Pharmacogenetics 14:587-94. 2004
    ..of VMAT2 function, but one that affects a highly conserved residue may increase sensitivity to the inhibitor tetrabenazine. The results illustrate the relationship between conservation of the affected residue, the nature of the ..
  34. ncbi The role of radiotracer imaging in Parkinson disease
    B Ravina
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    Neurology 64:208-15. 2005
    ..Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer...
  35. ncbi Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder
    Paz Toren
    Tel Aviv Community Mental Health Center and the Sackler Faculty of Medicine, Tel Aviv University, Israel
    Eur Neuropsychopharmacol 15:159-62. 2005
    ..It remains unclear whether the under-expression of platelet VMAT2 in ADHD children is reflective of a parallel change in the brain, and whether it is primary or an epiphenomenon of ADHD...
  36. ncbi Identification of tissue-restricted transcripts in human islets
    Antonella Maffei
    Institute of Genetics and Biophysics Adriano Buzzati Traverso, National Research Center, Naples, Italy
    Endocrinology 145:4513-21. 2004
    ..We report here the first comparison of gene expression profiles of human islets with other tissues and the identification of a target molecule with possible use in determining islet cell masses...
  37. pmc Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters
    Dennis K Miller
    College of Pharmacy, University of Kentucky, Lexington, KY, 40536 0082, USA
    J Pharmacol Exp Ther 310:1035-45. 2004
    ....
  38. ncbi Electrochemical monitoring of transport by a vesicular monoamine transporter expressed in Xenopus oocytes
    Janet Whitley
    Medical Science, Indiana University School of Medicine, Jordan Hall 104, Bloomington, IN 47405 6401, USA
    J Neurosci Methods 133:191-9. 2004
    ..Transport by rVMAT2-I483A/L484A-injected oocytes was reduced to control levels by tetrabenazine, a known inhibitor of VMAT transport activity...
  39. ncbi Raclopride studies of dopamine release: dependence on presynaptic integrity
    Doris J Doudet
    Department of Medicine, Division of Neurology and Pacific Parkinson Research Center and TRIUMF DJD, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Psychiatry 54:1193-9. 2003
    ..The mechanism responsible for the decrease in raclopride binding is still unclear...
  40. ncbi VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET
    Raul de la Fuente-Fernandez
    Pacific Parkinson s Research Centre, University of British Columbia, Vancouver, B C, Canada
    Synapse 49:20-8. 2003
    ..This is in keeping with a role for VMAT2 in other cellular processes (i.e., sequestration and release from the cell of potential toxic products), in addition to its importance for the quantal release of monoamines...
  41. ncbi Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons
    Carine Cleren
    Unité de Neuropsychopharmacologie Expérimentale, UMR 6036 CNRS, IFRMP 23, 22 Boulevard Gambetta, 76183 Rouen Cedex, France
    Brain Res 989:187-95. 2003
    ..The hypothermia prevented both 6-OHDA and MPP(+)-induced neurotoxicity. We finally reported that VMAT2 inhibition potentiates both MPP(+) and 6-OHDA neurotoxicity...
  42. ncbi Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge
    David S Segal
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA
    Neuropsychopharmacology 28:1730-40. 2003
    ....
  43. ncbi Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA
    S Gilman
    Department of Neurology University of Michigan, Ann Arbor, USA
    Neurology 61:35-9. 2003
    ..To explore the neurochemical basis of obstructive sleep apnea (OSA) in multiple-system atrophy (MSA)...
  44. ncbi REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA
    S Gilman
    Department of Neurology, University of Michigan, Ann Arbor, USA
    Neurology 61:29-34. 2003
    ..To explore the neurochemical basis of REM sleep behavior disorder (RBD) in multiple-system atrophy (MSA)...
  45. ncbi Decreased platelet vesicular monoamine transporter density in habitual smokers
    Karin Schwartz
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Eur Neuropsychopharmacol 15:235-8. 2005
    ..The decreased density of the VMAT2 in the platelets of smokers may reflect nicotine induced desensitization of VMAT2, a phenomenon that may be relevant to the addictive properties of nicotine...
  46. ncbi Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography
    Robert A Koeppe
    Division of Nuclear Medicine, Department of Radiology, The University of Michigan, Ann Arbor, MI, USA
    Alzheimers Dement 4:S67-76. 2008
    ..We used positron emission tomography (PET) in attempts to differentiate these disorders...
  47. ncbi Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography
    Erkki Tupala
    Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, Kuopio, Finland
    Psychiatry Res 163:70-5. 2008
    ..Although type 1 alcoholics have been reported to have up to 36% lower striatal dopamine transporter levels than controls, the results suggest that the density of their dopaminergic nerve terminals is not altered...
  48. ncbi Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease
    W R Wayne Martin
    Division of Neurology, University of Alberta, Edmonton, Alberta
    Ann Neurol 63:388-94. 2008
    ....
  49. ncbi [Quick and simple synthesis of (11)C-(+)-alpha-dihydrotetrabenazine to be used as a PET radioligand of vesicular monoamine transporters]
    G Quincoces
    Unidad de Radiofarmacia, Servicio de Medicina Nuclear, Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
    Rev Esp Med Nucl 27:13-21. 2008
    ....
  50. pmc VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease
    Ming Kai Chen
    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Neurochem 105:78-90. 2008
    ..Genetic or environmental factors that decrease VMAT2 function may be important determinants of PD...
  51. ncbi Neurotoxicity in murine striatal dopaminergic pathways following long-term application of low doses of permethrin and MPTP
    Jinghong Kou
    Neurotoxicology Laboratory, Department of Entomology, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
    Toxicol Lett 171:154-61. 2007
    ..3)H]Tetrabenazine (TBZ) binding assay for expression of striatal vesicular monoamine transporter (VMAT) showed no effect of PM, ..
  52. pmc Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters
    Mei Ping Kung
    Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Nucl Med Biol 34:239-46. 2007
    ..From these findings, we conclude that [(18)F]FP-(+)-DTBZ is a sensitive and selective tracer for VMAT2 binding sites and it may be useful for in vivo evaluation of diseases relating to changes of monoamine neuronal integrity...
  53. ncbi In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD
    Vesna Sossi
    Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada
    J Cereb Blood Flow Metab 27:1407-15. 2007
    ..Quantitative PET results can thus be obtained even for severely lesioned animals with the striatum on one side not clearly visible provided accurate image analysis methods are used...
  54. ncbi Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain
    Michael R Kilbourn
    Department of Radiology, Division of Nuclear Medicine, University of Michigan Medical School, Ann Arbor 48109, USA
    Exp Neurol 188:387-90. 2004
    ....
  55. ncbi Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters
    Rajesh Goswami
    Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Nucl Med Biol 33:685-94. 2006
    ..for VMAT2 binding sites in rat striatal homogenates, whereas the known compounds (+/-)-DTBZ and (+/-)-tetrabenazine (TBZ) showed K(i) values of 1.7+/-0.2 and 1.3+/-0.1 nM, respectively...
  56. ncbi Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission
    Daniel R Andersson
    Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Box 431, SE 405 30 Goteborg, Sweden
    Eur J Neurosci 24:617-24. 2006
    ..The vesicular monoamine transporter inhibitor tetrabenazine (100 microm) was administered locally in substantia nigra as well as in striatum...
  57. ncbi Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography
    Elissa M Strome
    Pacific Parkinson s Research Centre, University of British Columbia, Purdy Pavilion M36, 2221 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada
    Mol Imaging Biol 8:292-9. 2006
    ..This evaluation can be performed in vivo, through evaluation of dopamine (DA)-dependent motor function or with small animal positron emission tomography (microPET), or at postmortem, by examining markers for DA neurons...
  58. ncbi 11C-DTBZ and 18F-FDG PET measures in differentiating dementias
    Robert A Koeppe
    Division of Nuclear Medicine, Department of Radiology, University of Michigan School of Medicine, 3480 Kresge III, Box 0552, Ann Arbor, MI 48109, USA
    J Nucl Med 46:936-44. 2005
    ....
  59. ncbi The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study
    Vesna Sossi
    Department of Physics and Astronomy, University of British Columbia, 6224 Agricultural Rd, Vancouver V6T 1Z1, Canada
    Phys Med Biol 50:2859-69. 2005
    ..With measured attenuation correction, the COVs were on average 100% higher. The presented method can be used to examine the contribution of a variety of imaging conditions to the uncertainty of biologically meaningful parameters...
  60. ncbi Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Isabelle Boileau
    Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada
    J Neurosci 28:9850-6. 2008
    ..If correct, (+)[(11)C]DTBZ might be a useful imaging probe to correlate changes in brain dopamine stores and behavior in users of methamphetamine...
  61. ncbi Increased platelet vesicular monoamine transporter density in adult schizophrenia patients
    Michal Zucker
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur Neuropsychopharmacol 12:343-7. 2002
    ..The increased platelet VMAT2 density may indicate a schizophrenia-related hyperactivity of the monoaminergic system or an adaptive response to chronic drug treatment...
  62. ncbi Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors
    J M Brown
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 298:1150-3. 2001
    ..Furthermore, results indicate that D(2) receptor activation, per se, is sufficient to increase vesicular DA uptake...
  63. ncbi Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys
    Onofre T DeJesus
    Medical Physics Department, University of Wisconsin Medical School, 1530 Medical Sciences Center, 1300 University Avenue, Madison, WI 53706, USA
    Synapse 44:246-51. 2002
    The effect of tetrabenazine (TBZ) pretreatment on the striatal uptake of exogenous L-DOPA in vivo was assessed noninvasively in rhesus monkeys by positron emission tomography (PET) using the tracer [(18)F]-FluoroDOPA (FDOPA)...
  64. ncbi Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers
    M Suzuki
    Department of Radiology (Division of Nuclear Medicine, The University of Michigan, Ann Arbor, Michigan, USA
    Synapse 41:329-36. 2001
    ..There is also markedly reduced expression of ChAT by surviving cholinergic striatal interneurons...
  65. ncbi Phencyclidine increases vesicular dopamine uptake
    Michael J Crosby
    Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
    Eur J Pharmacol 438:75-8. 2002
    ..These data demonstrate a heretofore unreported mechanism that may contribute to the ability of PCP to influence dopamine neuronal function and exert its pharmacological effects...
  66. ncbi Cloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules
    M Howell
    Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, OH 45267 0524
    FEBS Lett 338:16-22. 1994
    ..Also, the recombinant bovine adrenal transporter is highly sensitive to tetrabenazine, in sharp contrast to the rat adrenal transporter...
  67. ncbi Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors
    Veronica Sandoval
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Neurosci 22:8705-10. 2002
    ..These observations suggest a role for DA in the MPD-induced redistribution of VMAT-2. The implications of this phenomenon will be discussed...
  68. ncbi Functional identification and molecular cloning of a human brain vesicle monoamine transporter
    J D Erickson
    Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, Maryland
    J Neurochem 61:2314-7. 1993
    ..55 microM. Reserpine and tetrabenazine, inhibitors of two monoamine binding sites, effectively blocked [3H]5-HT accumulation with Ki values of 34 and ..
  69. ncbi Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity
    J Paul Hansen
    Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
    J Pharmacol Exp Ther 300:1093-100. 2002
    ..Taken together, these results reveal several differences between effects of MDMA and previously reported METH on DAT and VMAT-2; differences that may underlie the dissimilar neurotoxic profile of these agents...
  70. ncbi 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged
    Joseph Knoll
    Department of Pharmacology and Pharmacotherapy, Faculty of General Medicine, Semmelweis University, P O B 370, H 1445 Budapest, Hungary
    Life Sci 71:1975-84. 2002
    The subcutaneous administration of 1 mg/kg tetrabenazine, once daily for 5 days, which depletes the catecholamine stores in the brain, significantly inhibits in rats the acquisition of a two-way conditioned avoidance reflex in the ..
  71. ncbi Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice
    F Fumagalli
    Howard Hughes Medical Institute Laboratories, Departments of Cell Biology and Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosci 19:2424-31. 1999
    ....
  72. ncbi Vesicular monoamine transporters heterologously expressed in the yeast Saccharomyces cerevisiae display high-affinity tetrabenazine binding
    R Yelin
    Alexander Silberman Institute of Life Sciences, Hebrew University, Givat Ram, Jerusalem 91904, Israel
    Biochim Biophys Acta 1510:426-41. 2001
    ..In this report we describe for the first time the heterologous expression of a neurotransmitter transporter in the yeast S. cerevisiae...
  73. ncbi Mutant mouse strains as models for in vivo radiotracer evaluations: [11C]methoxytetrabenazine ([11C]MTBZ) in tottering mice
    M R Kilbourn
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Nucl Med Biol 22:565-7. 1995
    ....
  74. ncbi Norepinephrine triggers Ca2+-dependent exocytosis of 5-hydroxytryptamine from rat pinealocytes in culture
    Hiroshi Yamada
    Department of Biochemistry, Faculty of Pharmaceutical Sciences, Okayama University, Okayama, Japan
    J Neurochem 81:533-40. 2002
    ..Bafilomycin A1, an inhibitor of vacuolar H+-ATPase, and reserpine and tetrabenazine, inhibitors of vesicular monoamine transporter, all decreased the storage of vesicular 5-HT followed by ..
  75. ncbi In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies
    Michael R Kilbourn
    Division of Nuclear Medicine, Department of Radiology, 3480 Kresge III Bldg, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Synapse 43:188-94. 2002
    ..Specific binding of (+)-alpha-[(11)C]dihydrotetrabenazine was blocked by co-infusion of tetrabenazine, but was unaffected by administration of methylphenidate, haloperidol, or apomorphine...
  76. ncbi Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2
    Moshe Rehavi
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Eur Neuropsychopharmacol 12:261-8. 2002
    ..Haloperidol induced an increase in the serotonin transporter in the striatum and the core of the nucleus accumbens. The special effect of clozapine on VMAT(2) expression may be relevant to its unique therapeutic advantages...
  77. ncbi Pharmacological options for the treatment of Tourette's disorder
    F J Jimenez-Jimenez
    Department of Medicine Neurology, Hospital Principe de Asturias, Universidad de Alcala, Alcala De Henares Madrid, and Neuro Magister S L Company, Madrid, Spain
    Drugs 61:2207-20. 2001
    ..ziprasidone) and other dopaminergic drugs (fluphenazine, sulpiride, tiapride, metoclopramide, piquindone, tetrabenazine), clonazepam, calcium channel antagonists, botulinum toxin, dopamine agonists, selegiline, and other drugs is ..
  78. pmc Modulation of gastrin processing by vesicular monoamine transporter type 1 (VMAT1) in rat gastrin cells
    I Hussain
    Physiological Laboratory, University of Liverpool, Liverpool, UK
    J Physiol 517:495-505. 1999
    ..was stereospecific and sensitive to reserpine (50 nM), which blocks VMAT1 and VMAT2, but resistant to tetrabenazine, which is a selective inhibitor of VMAT2. 4...
  79. ncbi Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures
    J F Reinhard
    Division of Medicinal Biochemistry, Burroughs Wellcome Co, Research Triangle Park, North Carolina 27709
    J Neurochem 55:311-20. 1990
    ..concentration dependent and significantly enhanced by inhibitors of catecholamine vesicular uptake (reserpine, tetrabenazine, or Ro 4-1284)...
  80. pmc PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine
    Joanna S Fowler
    Brookhaven National Laboratory, Upton, New York, USA
    J Nucl Med 48:1724-32. 2007
    ....
  81. ncbi Neuropharmacological studies on Fusarium toxins--I: Total toxin extract from Fusarium moniliforme
    S Ganguli
    Department of Pharmacology, Banaras Hindu University, Varanasi, India
    Indian J Exp Biol 34:408-17. 1996
    ..MES seizures, potentiated PTZ and tryptamine seizures, antagonised reserpine induced syndrome, attenuated tetrabenazine and morphine induced catalepsy and potentiated haloperidol catalepsy...
  82. pmc Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease
    Samuel Frank
    Boston University School of Medicine, 72 East Concord St, C329, Boston, Massachusetts, USA
    Neuropsychiatr Dis Treat 6:657-65. 2010
    ..b>Tetrabenazine (TBZ) is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although ..
  83. ncbi Alterations in serotonin parameters in brain of thiamine-deficient rats are evident prior to the appearance of neurological symptoms
    D D Mousseau
    Department of Psychiatry, Hopital Saint Luc, Montreal, Quebec, Canada
    J Neurochem 67:1113-23. 1996
    ..appear to represent changes in the density of the postsynaptic 5-HT2A receptor population rather than the "tetrabenazine-sensitive" vesicular monoamine transporter, are evident before the appearance of histopathologic lesions and ..
  84. ncbi Neuropharmacological studies on Fusarium toxins--II: Total toxin extract from F. oxysporum
    S Ganguli
    Department of Pharmacology, Banaras Hindu University, Varanasi, India
    Indian J Exp Biol 34:418-26. 1996
    ..It antagonised morphine, tetrabenazine and haloperidol catalepsy...
  85. pmc Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter
    J D Erickson
    Section on Molecular Neuroscience, National Institute of Mental Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 93:5166-71. 1996
    ..are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2...
  86. ncbi Hypericum grandifolium Choisy: a species native to Macaronesian Region with antidepressant effect
    C C Sánchez-Mateo
    Departamento de Farmacologia, Facultad de Farmacia, Universidad de La Laguna, c Astrofísico Francisco Sánchez s n, 38071 La Laguna, Tenerife, Spain
    J Ethnopharmacol 121:297-303. 2009
    ..Studies have shown that methanol extract of Hypericum grandifolium Choisy is active in tetrabenazine-induced ptosis and forced swimming tests...
  87. ncbi Pharmacological management of Huntington's disease: an evidence-based review
    Raphael M Bonelli
    University Clinic of Psychiatry, Department of Psychiatry, Graz Medical University, Auenbruggerplatz 31, A 8036 Graz, Austria
    Curr Pharm Des 12:2701-20. 2006
    ..Despite the increasing body of published reports on pharmacological interventions in Huntington's disease (HD), an evidence based review (EBR) of treatment studies has not yet been published...
  88. ncbi Antidepressant properties of some Hypericum canariense L. and Hypericum glandulosum Ait. extracts in the forced swimming test in mice
    C C Sánchez-Mateo
    Departamento de Farmacologia, Facultad de Farmacia, Universidad de La Laguna, c Astrofísico Francisco Sánchez s n, 38071, La Laguna, Tenerife, Spain
    J Ethnopharmacol 97:541-7. 2005
    ..and Hypericum glandulosum Ait. was active in the tetrabenazine and forced swimming test...
  89. ncbi Reserpine causes biphasic nociceptive sensitivity alteration in conjunction with brain biogenic amine tones in rats
    T Oe
    Department of Pain Research, Pharmacology Research Labs, Drug Discovery Research, Astellas Pharma Inc, 21 Miyukigaoka, Tsukuba, Ibaraki 305 8585, Japan
    Neuroscience 169:1860-71. 2010
    ..muscle pressure, tactile, cold, and heat) stimuli were assessed in acute phase (up to 24 h after reserpine or tetrabenazine injection) and chronic phase (on day 2 or later) in rats. A single injection of reserpine (3 mg/kg s.c...
  90. ncbi [The study and treatment of dystonias in childhood]
    S I Pascual-Pascual
    Hospital Universitario La Paz, 28046 Madrid, Espana
    Rev Neurol 43:S161-8. 2006
    ..Dystonia is after spasticity and tics the most common movement disorder in childhood. The etiology, diagnostic methods and treatment of childhood dystonia is reviewed...
  91. ncbi A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse
    Linda P Dwoskin
    College of Pharmacy, University of Kentucky, Rose Street, Lexington, KY 40536 0082, USA
    Biochem Pharmacol 63:89-98. 2002
    ..of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2)...
  92. ncbi [Intrathecal perfusion pump with baclofen in generalized dystonia]
    M A Grande
    , Hospital Universitario Virgen Macarena, Sevilla,
    Rev Neurol 30:138-40. 2000
    ..intrathecal baclofen infusion in a case of hereditary generalized dystonia refractory to anticholinergics, tetrabenazine, pimozide, L-dopa, benzodiazepines and thalamotomy...
  93. ncbi Characterization of the striatal dopaminergic neurotransmission in MEN2B mice with elevated cerebral tissue dopamine
    Jelena Mijatovic
    Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, Finland
    J Neurochem 105:1716-25. 2008
    ..Augmented effects of alpha-methyl-para-tyrosine (alphaMT, an inhibitor of TH) and tetrabenazine (VMAT2 blocker) on DA levels suggest that also storage of DA is increased in MEN2B mice...
  94. ncbi Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter
    F Darchen
    Institut de Biologie Physico Chimique, Paris, France
    Biochemistry 28:1692-7. 1989
    ..It is proposed that the transporter exists in two different conformations which bind exclusively either tetrabenazine (TBZ) or RES and which are in equilibrium...
  95. ncbi Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe
    Anupama Gopalakrishnan
    Department of Pharmacology, University of Wisconsin Madison, Madison WI 53705, USA
    Mol Pharmacol 72:1567-75. 2007
    ..studies using photoaffinity-labeling techniques in characterizing the VMAT2-specific ligands ketanserin and tetrabenazine, this study describes the synthesis and characterization of a fluorenone-based compound, iodoaminoflisopolol (..
  96. ncbi Advances in the pharmacological management of Huntington's disease
    Samuel Frank
    Boston University School of Medicine, Boston, Massachusetts, USA
    Drugs 70:561-71. 2010
    ..b>Tetrabenazine is one of the better studied and more effective agents for reducing chorea, although with a risk of ..
  97. ncbi Subcellular distribution of acetylcholinesterase forms in chromaffin cells. Do chromaffin granules contain a specific secretory acetylcholinesterase?
    S Bon
    Laboratoire de Neurobiologie, Centre National de la Recherche Scientifique, Unité Associée 295, Paris, France
    Eur J Biochem 190:221-32. 1990
    ..We obtained evidence for the existence of a lighter fraction also containing chromogranin A, tetrabenazine-binding sites and Gna4 AChE, which may correspond to immature, incompletely loaded granules or to partially ..
  98. ncbi Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both
    Godelieve A M Tytgat
    Center of Microscopic Research, Academical Medical Center, Amsterdam, The Netherlands
    Exp Hematol 30:555-63. 2002
    ..MIBG is taken up in platelets via the serotonin transporter. Given the delayed appearance and long duration of the thrombocytopenia, it seems likely that the precursor megakaryocytes are the primary targets of [131I]MIBG radiotoxicity...
  99. pmc Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series
    Carsten Saft
    Department of Neurology, Huntington Center NRW, St, Josef Hospital, Bochum, Germany
    BMC Neurol 6:11. 2006
    ..with antidopaminergic neuroleptics like haloperidol, olanzapine and tiaprid or dopamine depleting drugs like tetrabenazine. Some patients with hyperkinesia, however, react to treatment with antidopaminergic drugs by developing ..
  100. ncbi Paroxysmal dyskinesias
    Shyamal H Mehta
    Shyamal H Mehta, MD, PhD Movement Disorders Program, Department of Neurology, 1429 Harper Street, HF 1121, Augusta, GA 30912, USA
    Curr Treat Options Neurol 11:170-8. 2009
    ..Drugs such as acetazolamide, anticholinergics, levodopa, and tetrabenazine have been inconsistently successful...
  101. ncbi Treatment of hyperkinetic movement disorders
    Joseph Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Lancet Neurol 8:844-56. 2009
    ..In addition to tetrabenazine, a monoamine-depleting drug, new formulations of botulinum toxin are being increasingly used in the treatment ..

Research Grants19

  1. Structural Studies of Vesicular Monoamine Transporters
    SATINDER KAUR SINGH; Fiscal Year: 2013
    ..Currently-prescribed therapeutics include the inhibitors reserpine [RES] and tetrabenazine [TBZ]...
  2. A Novel VMAT 2 Radioligand for Imaging Parkinson's
    Gilles Tamagnan; Fiscal Year: 2004
    ..One presynaptic cell marker for VMAT 2 is l lc labeled tetrabenazine. This tracer has been used in a limited number of PD patients owing to the logistical difficulty in performing ..
  3. New PET Radiotracers-Monoamine Transporters
    Michael Kilbourn; Fiscal Year: 2003
    ....
  4. MURINE MODEL OF CAG REPEAT DISEASES
    Roger Albin; Fiscal Year: 2002
    ..These experiments will establish HPRT-CAG mice as important tools for understanding neurodegeneration in CAG repeat diseases and enable accurate preclinical evaluation of interventions for CAG repeat diseases. ..
  5. Evaluating Striatal Function in a Murine HD Model
    Roger Albin; Fiscal Year: 2007
    ..Validation of these methods will provide new and useful behavioral tools for evaluating murine disease models. [unreadable] [unreadable] [unreadable]..
  6. Conference on the Diagnosis of Multiple System Atrophy
    Sid Gilman; Fiscal Year: 2006
    ..This conference will assist with early diagnosis by developing new guidelines for diagnosis using newly available imaging and neuropathological criteria. [unreadable] [unreadable] [unreadable]..
  7. Implementation of [18F] FEOBV for VAChT Imaging with PET
    Robert Koeppe; Fiscal Year: 2004
    ..g. AD). R33 (Year 5): Conclude clinical evaluations in normal control and patient groups. ..
  8. CREATINE THERAPY TO TREAT HUNTINGTON'S DISEASE: A PHASE 3 STUDY
    Steven M Hersch; Fiscal Year: 2010
    ....
  9. Addiction and the Brain: Are We Hard Wired to Abuse Drugs
    Joanna Fowler; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  10. Neurochemical mediation of placebo responses in humans
    Jon Kar Zubieta; Fiscal Year: 2006
    ..abstract_text> ..
  11. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2002
    ....
  12. Creatine Therapy for Huntington's Disease
    Steven Hersch; Fiscal Year: 2004
    ..These studies are intended to provide the basis of a subsequent phase III trial of creatine in HD. ..
  13. Neurochemical Endophenotype Responses to Pain-Stress
    Jon Kar Zubieta; Fiscal Year: 2007
    ....
  14. RADIOTRACER R & D IN NUCLEAR MEDICINE AND NEUROSCIENCES
    Joanna Fowler; Fiscal Year: 2004
    ....
  15. Transcription and Therapy for HD: from Molecules to Man
    Steven Hersch; Fiscal Year: 2007
    ..The projects are highly integrated, each interacting extensively with all the others to contribute to the overall program. The three institutions involved insure that the program will exist in a highly supportive environment. ..
  16. HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION
    Steven Hersch; Fiscal Year: 2003
    ..In Specific Aim 4, we will examine apoptosis as a mechanism of cell death in transgenic HD animals by direct examination and by crossing tem with transgenic animal lines relevant to apoptotic death. ..
  17. CATECHOLAMINES, ANTIOXIDANTS AND OXIDATIVE STRESS
    Kandatege Wimalasena; Fiscal Year: 2003
    ..abstract_text> ..
  18. Molecular & Behavioral Effects of Low Level Mn Exposure
    TOMAS GUILARTE; Fiscal Year: 2008
    ..The knowledge gained will help set future public health policies and guidelines to limit Mn exposures in occupational settings and to the general population. ..
  19. Mu Opioid Mediated Stress Regulation in BPD
    Jon Kar Zubieta; Fiscal Year: 2006
    ..This information is critical for the understanding of the biological mechanisms underlying the symptomatology of BPD, and to guide future research and treatment interventions in this common but poorly understood illness. ..